Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385580
Status:
COMPLETED
Last Update Posted:
2013-04-30
First Post:
2006-10-04
Brief Title:
Phase II Study of Dasatinib BMS-354825 for Androgen-deprived Progressive Prostate Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase II Study of Dasatinib BMS-354825 for Androgen-deprived Progressive Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2012-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen PSA who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone LHRH treatment respond to dasatinib The safety of this treatment will also be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None